Five Prime Therapeutics, Inc. (NASDAQ: FPRX), a clinical-stage biotechnology company focused on developing immune modulators and precision therapies for solid tumor cancers, will participate in the 38th Annual J.P. Morgan Healthcare Conference on Thursday, January 16, 2020. William Ringo, who is Five Prime’s Chairman and interim Chief Executive Officer, will represent the company and respond to questions from investors. He is scheduled to present at 7:30 a.m. PT (10:30 a.m. ET).
Investors and other interested parties will be able to access a live audio webcast of the presentation by visiting http://investor.fiveprime.com/events-presentations. A replay of the presentation will also be available on the Five Prime website for 30 days after the conference.
About Five Prime
Five Prime Therapeutics, Inc. develops innovative protein therapeutics to improve the lives of patients with cancer. The company focuses on developing immune modulators and precision therapies for solid tumor cancers paired with companion diagnostics to identify patients who are most likely to benefit from treatment with Five Prime’s product candidates. The company’s product candidates have innovative mechanisms of action and address patient populations in need of better therapies. Five Prime has entered into strategic collaborations with leading global pharmaceutical companies and has promising product candidates in clinical and preclinical development. For more information, please visit www.fiveprime.com.
Source: Five Prime Therapeutics, Inc.